Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia.

Megan HerodesLindsey J AndersonSamuel ShoberEllen A SchurSolomon A GrafNicola AmmerRamiro SalasMarco MarcelliJose M Garcia

Published in: Journal of cachexia, sarcopenia and muscle (2023)

Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. Longer term administration should be evaluated for mitigation of cancer-induced reductions in body weight, appetite and QOL in larger studies.

Keyphrases

body weight
clinical trial
double blind
papillary thyroid
study protocol
high glucose
placebo controlled
phase iii
climate change
diabetic rats
squamous cell
preterm infants
physical activity
open label
phase ii
randomized controlled trial
squamous cell carcinoma
case control
childhood cancer